HIV portends a poor prognosis in myelodysplastic syndromes

Justin D. Kaner, Santiago Thibaud, Sakshi Jasra, Yanhua Wang, Murali Janakiram, Anjali Sharma, Ashwin Sridharan, Harold Elias, Rahul Polineni, Amer Assal, Louis Weiss, Ira Braunschweig, Ulrich Steidl, Kith Pradhan, Aditi Shastri, Mark Chaitowitz, Barry Zingman, Britta Will, Ioannis Mantzaris, Amit Verma

Research output: Contribution to journalArticle

Abstract

Even though HIV is associated with worse prognosis in many malignancies, the clinical course of myelodysplastic syndrome (MDS) in HIV + patients has not been well studied. Determining the clinical presentation and outcomes of MDS in these patients would be important for future diagnostic strategies, as anemia and other cytopenias are commonly seen in HIV + patients. Unique data mining software was used to identify cases of MDS or AML in adult patients who were also HIV + at Albert Einstein/Montefiore Medical Center between 1 January 2003 and 1 January 2017. Using Chi-Square and Fisher’s exact test, characteristics of the HIV + MDS patients were compared to 135 HIV − MDS patients from the same institution diagnosed between 1997 and 2011. Fourteen biopsy proven MDS patients were identified with concomitant HIV. HIV + MDS patients presented at a younger age (59 vs. 71 yrs, p =.001) had higher risk disease, faster progression to acute leukemia, and worse overall survival (median survival 11.2 vs. 69.1 mo, p <.001) compared to HIV − MDS controls. Additionally, there was a higher prevalence of clonal-hematopoiesis related mutations (ASXL1, DNMT3A) and a higher proportion of patients with high risk cytogenetics. Analysis of the largest single center cohort of HIV + MDS patients demonstrated that these individuals present at a significantly younger age and with higher risk disease than their HIV − counterparts.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StatePublished - Jan 1 2019

Fingerprint

Myelodysplastic Syndromes
HIV
Data Mining
Survival
Hematopoiesis
Cytogenetics
Disease Progression
Anemia
Leukemia
Software
Biopsy

Keywords

  • Cytopenias
  • HIV
  • MDS

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

HIV portends a poor prognosis in myelodysplastic syndromes. / Kaner, Justin D.; Thibaud, Santiago; Jasra, Sakshi; Wang, Yanhua; Janakiram, Murali; Sharma, Anjali; Sridharan, Ashwin; Elias, Harold; Polineni, Rahul; Assal, Amer; Weiss, Louis; Braunschweig, Ira; Steidl, Ulrich; Pradhan, Kith; Shastri, Aditi; Chaitowitz, Mark; Zingman, Barry; Will, Britta; Mantzaris, Ioannis; Verma, Amit.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

@article{8c05ff1bc4cf48a9ba5eb2aacbb127a7,
title = "HIV portends a poor prognosis in myelodysplastic syndromes",
abstract = "Even though HIV is associated with worse prognosis in many malignancies, the clinical course of myelodysplastic syndrome (MDS) in HIV + patients has not been well studied. Determining the clinical presentation and outcomes of MDS in these patients would be important for future diagnostic strategies, as anemia and other cytopenias are commonly seen in HIV + patients. Unique data mining software was used to identify cases of MDS or AML in adult patients who were also HIV + at Albert Einstein/Montefiore Medical Center between 1 January 2003 and 1 January 2017. Using Chi-Square and Fisher’s exact test, characteristics of the HIV + MDS patients were compared to 135 HIV − MDS patients from the same institution diagnosed between 1997 and 2011. Fourteen biopsy proven MDS patients were identified with concomitant HIV. HIV + MDS patients presented at a younger age (59 vs. 71 yrs, p =.001) had higher risk disease, faster progression to acute leukemia, and worse overall survival (median survival 11.2 vs. 69.1 mo, p <.001) compared to HIV − MDS controls. Additionally, there was a higher prevalence of clonal-hematopoiesis related mutations (ASXL1, DNMT3A) and a higher proportion of patients with high risk cytogenetics. Analysis of the largest single center cohort of HIV + MDS patients demonstrated that these individuals present at a significantly younger age and with higher risk disease than their HIV − counterparts.",
keywords = "Cytopenias, HIV, MDS",
author = "Kaner, {Justin D.} and Santiago Thibaud and Sakshi Jasra and Yanhua Wang and Murali Janakiram and Anjali Sharma and Ashwin Sridharan and Harold Elias and Rahul Polineni and Amer Assal and Louis Weiss and Ira Braunschweig and Ulrich Steidl and Kith Pradhan and Aditi Shastri and Mark Chaitowitz and Barry Zingman and Britta Will and Ioannis Mantzaris and Amit Verma",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2019.1633631",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - HIV portends a poor prognosis in myelodysplastic syndromes

AU - Kaner, Justin D.

AU - Thibaud, Santiago

AU - Jasra, Sakshi

AU - Wang, Yanhua

AU - Janakiram, Murali

AU - Sharma, Anjali

AU - Sridharan, Ashwin

AU - Elias, Harold

AU - Polineni, Rahul

AU - Assal, Amer

AU - Weiss, Louis

AU - Braunschweig, Ira

AU - Steidl, Ulrich

AU - Pradhan, Kith

AU - Shastri, Aditi

AU - Chaitowitz, Mark

AU - Zingman, Barry

AU - Will, Britta

AU - Mantzaris, Ioannis

AU - Verma, Amit

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Even though HIV is associated with worse prognosis in many malignancies, the clinical course of myelodysplastic syndrome (MDS) in HIV + patients has not been well studied. Determining the clinical presentation and outcomes of MDS in these patients would be important for future diagnostic strategies, as anemia and other cytopenias are commonly seen in HIV + patients. Unique data mining software was used to identify cases of MDS or AML in adult patients who were also HIV + at Albert Einstein/Montefiore Medical Center between 1 January 2003 and 1 January 2017. Using Chi-Square and Fisher’s exact test, characteristics of the HIV + MDS patients were compared to 135 HIV − MDS patients from the same institution diagnosed between 1997 and 2011. Fourteen biopsy proven MDS patients were identified with concomitant HIV. HIV + MDS patients presented at a younger age (59 vs. 71 yrs, p =.001) had higher risk disease, faster progression to acute leukemia, and worse overall survival (median survival 11.2 vs. 69.1 mo, p <.001) compared to HIV − MDS controls. Additionally, there was a higher prevalence of clonal-hematopoiesis related mutations (ASXL1, DNMT3A) and a higher proportion of patients with high risk cytogenetics. Analysis of the largest single center cohort of HIV + MDS patients demonstrated that these individuals present at a significantly younger age and with higher risk disease than their HIV − counterparts.

AB - Even though HIV is associated with worse prognosis in many malignancies, the clinical course of myelodysplastic syndrome (MDS) in HIV + patients has not been well studied. Determining the clinical presentation and outcomes of MDS in these patients would be important for future diagnostic strategies, as anemia and other cytopenias are commonly seen in HIV + patients. Unique data mining software was used to identify cases of MDS or AML in adult patients who were also HIV + at Albert Einstein/Montefiore Medical Center between 1 January 2003 and 1 January 2017. Using Chi-Square and Fisher’s exact test, characteristics of the HIV + MDS patients were compared to 135 HIV − MDS patients from the same institution diagnosed between 1997 and 2011. Fourteen biopsy proven MDS patients were identified with concomitant HIV. HIV + MDS patients presented at a younger age (59 vs. 71 yrs, p =.001) had higher risk disease, faster progression to acute leukemia, and worse overall survival (median survival 11.2 vs. 69.1 mo, p <.001) compared to HIV − MDS controls. Additionally, there was a higher prevalence of clonal-hematopoiesis related mutations (ASXL1, DNMT3A) and a higher proportion of patients with high risk cytogenetics. Analysis of the largest single center cohort of HIV + MDS patients demonstrated that these individuals present at a significantly younger age and with higher risk disease than their HIV − counterparts.

KW - Cytopenias

KW - HIV

KW - MDS

UR - http://www.scopus.com/inward/record.url?scp=85068566051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068566051&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1633631

DO - 10.1080/10428194.2019.1633631

M3 - Article

AN - SCOPUS:85068566051

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -